Our results do not support observations that individuals with the H1 haplotype have increased CSF t‐tau levels (Kauwe et al., 2008; Laws et al., 2007) and increased risk for AD or other tauopathies (Di Maria et al., 2010; Myers et al., 2005; Pittman et al., 2005), as our patients with the H2 haplotype had pathological CSF t‐tau and p‐tau levels. The gene discussed is MAPT; the disease is tauopathy.